$GRTSQ
Gritstone bio, Inc. Stock $grtsq

$grtsq Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023007022 Filed on March 09, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$2.443M	$4.262M	$19.95M
YoY Change	-66.03%	39.1%	-58.63%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.745M	$6.761M	$28.97M
YoY Change	-15.21%	1.18%	11.71%
% of Gross Profit
Research & Development	$30.51M	$29.42M	$111.4M
YoY Change	8.21%	12.44%	14.27%
% of Gross Profit
Depreciation & Amortization	$1.799M	$1.791M	$6.560M
YoY Change	13.22%	14.44%	3.36%
% of Gross Profit
Operating Expenses	$37.26M	$36.18M	$140.4M
YoY Change	3.06%	10.15%	13.73%
Operating Profit	-$34.82M		-$120.4M
YoY Change	20.21%		60.12%
Interest Expense	$844.0K	$629.0K	$1.235M
YoY Change	1695.74%	4093.33%	872.44%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$33.98M	-$31.29M	-$119.7M
YoY Change	17.52%	5.11%	59.41%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$33.98M	-$31.29M	-$119.7M
YoY Change	17.52%	5.11%	59.41%
Net Earnings / Revenue	-1390.99%	-734.16%	-600.09%
Basic Earnings Per Share	-$0.30		-$1.32
Diluted Earnings Per Share	-$0.30	-$0.36	-$1.32
COMMON SHARES
Basic Shares Outstanding	87.66M	83.37M	90.92M
Diluted Shares Outstanding	114.4M		90.92M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$145.8M	$175.9M	$171.9M
YoY Change	-15.31%	-14.73%	-14.75%
Cash & Equivalents	$47.13M	$55.50M	$38.19M
Short-Term Investments	$98.68M	$120.4M	$116.4M
Other Short-Term Assets	$728.0K	$567.0K	$10.33M
YoY Change	-26.46%	-34.53%	-41.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$154.8M	$182.9M	$182.9M
YoY Change	-19.6%	-17.1%	-17.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$20.37M	$21.34M	$38.82M
YoY Change	-8.61%	-1.33%	-12.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$4.031M	$4.031M
YoY Change		-12.69%	-12.69%
Other Assets	$19.21M	$15.03M	$15.03M
YoY Change	180.23%	79.84%	79.84%
Total Long-Term Assets	$55.19M	$57.88M	$57.88M
YoY Change	8.28%	0.63%	0.63%
TOTAL ASSETS
Total Short-Term Assets	$154.8M	$182.9M	$182.9M
Total Long-Term Assets	$55.19M	$57.88M	$57.88M
Total Assets	$210.0M	$240.8M	$240.8M
YoY Change	-13.77%	-13.43%	-13.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.975M	$8.694M	$8.694M
YoY Change	5.92%	105.53%	105.53%
Accrued Expenses	$3.123M	$4.124M	$20.98M
YoY Change	131.33%	903.41%	13.23%
Deferred Revenue	$2.801M	$5.131M
YoY Change	-77.27%	-70.17%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$24.67M	$34.80M	$34.80M
YoY Change	-27.62%	-12.9%	-12.9%
LONG-TERM LIABILITIES
Long-Term Debt	$29.58M	$19.35M	$19.35M
YoY Change
Other Long-Term Liabilities	$251.0K	$150.0K	$15.82M
YoY Change	-98.76%		-28.29%
Total Long-Term Liabilities	$29.83M	$19.50M	$35.17M
YoY Change	47.7%		59.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.67M	$34.80M	$34.80M
Total Long-Term Liabilities	$29.83M	$19.50M	$35.17M
Total Liabilities	$69.07M	$69.97M	$69.97M
YoY Change	27.25%	12.82%	12.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$555.1M	-$521.1M
YoY Change	29.0%	29.82%
Common Stock	$22.00K	$22.00K
YoY Change	10.0%	10.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$140.9M	$170.8M	$170.8M
YoY Change
Total Liabilities & Shareholders Equity	$210.0M	$240.8M	$240.8M
YoY Change	-13.77%	-13.43%	-13.43%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$33.98M	-$31.29M	-$119.7M
YoY Change	17.52%	5.11%	59.41%
Depreciation, Depletion And Amortization	$1.799M	$1.791M	$6.560M
YoY Change	13.22%	14.44%	3.36%
Cash From Operating Activities	-$40.10M	-$30.37M	-$115.9M
YoY Change	19.7%	27.73%	128.6%
INVESTING ACTIVITIES
Capital Expenditures	$1.567M	$1.483M	$5.872M
YoY Change	-13.52%	-211.5%	7.49%
Acquisitions
YoY Change
Other Investing Activities	$22.74M	-$44.67M	-$7.092M
YoY Change	140.74%	-1.38%	-93.73%
Cash From Investing Activities	$21.17M	-$46.15M	-$12.96M
YoY Change	177.35%	-1.02%	-89.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.647M	64.36M	83.10M
YoY Change	-1042.97%	95.78%	-23.6%
NET CHANGE
Cash From Operating Activities	-40.10M	-30.37M	-115.9M
Cash From Investing Activities	21.17M	-46.15M	-12.96M
Cash From Financing Activities	8.647M	64.36M	83.10M
Net Change In Cash	-10.27M	-12.16M	-45.81M
YoY Change	-61.58%	-67.59%	-24.24%
FREE CASH FLOW
Cash From Operating Activities	-$40.10M	-$30.37M	-$115.9M
Capital Expenditures	$1.567M	$1.483M	$5.872M
Free Cash Flow	-$41.67M	-$31.86M	-$121.8M
YoY Change	18.0%	41.91%	116.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q1	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2021-04-01
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001656634
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38663
CY2022	dei	Entity Registrant Name EntityRegistrantName	Gritstone bio, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4859534
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	5959 Horton Street
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Emeryville
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94608
CY2022	dei	City Area Code CityAreaCode	510
CY2022	dei	Local Phone Number LocalPhoneNumber	871-6100
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	GRTS
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	171700000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	87661978
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	San Mateo, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55498000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	93287000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	116389000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	108346000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	3977000
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	11285000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7014000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7672000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	182878000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	220590000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5290000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	6005000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21335000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21622000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17481000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22920000
CY2022Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	9739000
CY2021Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	2352000
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	4031000
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	4617000
CY2022Q4	us-gaap	Assets Assets	240754000
CY2021Q4	us-gaap	Assets Assets	278106000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8694000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4230000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8215000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6925000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4124000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	411000
CY2022Q4	grts	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	3343000
CY2021Q4	grts	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	3706000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5294000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7483000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5131000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	17201000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34801000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	39956000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	150000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15673000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18936000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3128000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19349000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0
CY2022Q4	us-gaap	Liabilities Liabilities	69973000
CY2021Q4	us-gaap	Liabilities Liabilities	62020000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86894901
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86894901
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69047878
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69047878
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	22000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	20000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	691910000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	617523000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-80000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-73000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-521071000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-401384000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	170781000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	216086000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	240754000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	278106000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19945000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48214000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4037000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	111403000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	97490000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	88643000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28970000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25933000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21411000
CY2022	us-gaap	Operating Expenses OperatingExpenses	140373000
CY2021	us-gaap	Operating Expenses OperatingExpenses	123423000
CY2020	us-gaap	Operating Expenses OperatingExpenses	110054000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-120428000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-75209000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-106017000
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1976000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	164000
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	715000
CY2022	us-gaap	Interest Expense InterestExpense	1235000
CY2021	us-gaap	Interest Expense InterestExpense	37000
CY2020	us-gaap	Interest Expense InterestExpense	12000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119687000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75082000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-105314000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-7000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-73000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-24000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-119694000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-75155000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-105338000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.95
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.95
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.79
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.79
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90918333
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90918333
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78885186
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78885186
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37792365
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37792365
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	134344000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	87704000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	910000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-24000
CY2020	grts	Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises	11000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	206000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7110000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-105314000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	166739000
CY2021	grts	Adjustments To Additional Paid In Capital Offering Costs Related To Sale Of Common Stock And Pre Funded Warrants AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants	-451000
CY2021	grts	Stock Issued During Period Value Purchase Agreement StockIssuedDuringPeriodValuePurchaseAgreement	20830000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	914000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-73000
CY2021	grts	Issuance Of Common Stock For Warrant Exercises Value IssuanceOfCommonStockForWarrantExercisesValue	49000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3360000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10552000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75082000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	216086000
CY2022	grts	Issuance Of Common Stock For Warrant Exercises Value IssuanceOfCommonStockForWarrantExercisesValue	34000
CY2022	grts	Tax Payments Related To Shares Withheld For Vested Restricted Stock Units TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits	890000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	549000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-7000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	186000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12557000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119687000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	170781000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119687000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75082000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-105314000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6560000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6347000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6644000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	372000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-817000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	122000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	392000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	12557000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	10552000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	7110000
CY2022	grts	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	9131000
CY2021	grts	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	8052000
CY2020	grts	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	7511000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-658000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3426000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	852000
CY2022	grts	Increase Decrease In Deposit And Other Assets Noncurrent IncreaseDecreaseInDepositAndOtherAssetsNoncurrent	7387000
CY2021	grts	Increase Decrease In Deposit And Other Assets Noncurrent IncreaseDecreaseInDepositAndOtherAssetsNoncurrent	614000
CY2020	grts	Increase Decrease In Deposit And Other Assets Noncurrent IncreaseDecreaseInDepositAndOtherAssetsNoncurrent	-49000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1879000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-419000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	826000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1290000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	593000
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1731000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	3509000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-859000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	662000
CY2022	grts	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	-363000
CY2021	grts	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	2653000
CY2020	grts	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	-725000
CY2022	grts	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-8915000
CY2021	grts	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-7925000
CY2020	grts	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-3801000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-15198000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	8633000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2821000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-115946000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50678000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-89102000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	141908000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	199905000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	8809000
CY2022	grts	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	134816000
CY2021	grts	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	82253000
CY2020	grts	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	72872000
CY2022	grts	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	0
CY2021	grts	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	4800000
CY2020	grts	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	5401000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5872000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5463000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3515000
CY2022	grts	Prepayments On Financing Lease PrepaymentsOnFinancingLease	0
CY2021	grts	Prepayments On Financing Lease PrepaymentsOnFinancingLease	238000
CY2020	grts	Prepayments On Financing Lease PrepaymentsOnFinancingLease	0
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12964000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-118553000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	65949000
CY2022	grts	Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts	0
CY2021	grts	Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts	0
CY2020	grts	Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts	125026000
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	19130000
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	420000
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	8394000
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	104000
CY2022	grts	Payments Of Financing Lease PaymentsOfFinancingLease	228000
CY2021	grts	Payments Of Financing Lease PaymentsOfFinancingLease	56000
CY2020	grts	Payments Of Financing Lease PaymentsOfFinancingLease	0
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	890000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	83098000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	108760000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	135801000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-45812000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-60471000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	112648000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110577000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171048000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58400000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64765000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110577000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171048000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1146000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	738000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	316000
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	2433000
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	69000
CY2020	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	5200000
CY2022	grts	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	1406000
CY2021	grts	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	6452000
CY2020	grts	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	3174000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	553000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	109000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2022	us-gaap	Interest Paid Net InterestPaidNet	647000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0
CY2020	us-gaap	Interest Paid Net InterestPaidNet	0
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119700000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75100000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-105300000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-115900000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50700000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-89100000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-521100000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-401400000
CY2022Q4	grts	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	175900000
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, determining the fair value of assets and liabilities, the fair value of right-of-use assets and lease liabilities, stock-based compensation expense, and transaction price and progress toward completion of performance obligation under the contracts with customers. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6300000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6600000
CY2022Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	600000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55498000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	93287000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	3977000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	11285000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5290000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	6005000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	64765000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	110577000
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2020	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	14500000
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company’s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of December 31, 2022, the Company has no off-balance sheet concentrations of credit risk.</span></p>
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y1M28D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	409000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6421425
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.04
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	995000
CY2022	grts	Percentage Of Realization Of Tax Benefit Upon Ultimate Settlement PercentageOfRealizationOfTaxBenefitUponUltimateSettlement	0.50
CY2020Q2	grts	Use Of Net Operating Losses Suspension Period For Medium And Large Business UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness	P3Y
CY2020Q2	grts	Use Of Business Incentive Tax Credits Period Cap UseOfBusinessIncentiveTaxCreditsPeriodCap	P3Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	500000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	158691000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	55000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	135000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	158611000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	194348000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	73000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	194275000
CY2022Q4	grts	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	175900000
CY2021Q4	grts	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	206300000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55500000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	93300000
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	120400000
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	113000000.0
CY2022	grts	Marketable Securities Realized Gain Loss Description MarketableSecuritiesRealizedGainLossDescription	no material realized gains or losses
CY2021	grts	Marketable Securities Realized Gain Loss Description MarketableSecuritiesRealizedGainLossDescription	no material realized gains or losses
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2020	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2022	grts	Fair Value Measurement Level1 To Level2 Transfers FairValueMeasurementLevel1ToLevel2Transfers	0
CY2021	grts	Fair Value Measurement Level1 To Level2 Transfers FairValueMeasurementLevel1ToLevel2Transfers	0
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	48773000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	41907000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	28782000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	22276000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21335000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21622000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6600000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	8797000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	7973000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	7511000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	7000
CY2022	us-gaap	Lease Cost LeaseCost	8797000
CY2021	us-gaap	Lease Cost LeaseCost	7973000
CY2020	us-gaap	Lease Cost LeaseCost	7518000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	8915000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	7925000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	5389000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1959000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6562000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3174000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.077
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.074
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8604000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	12527000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10658000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10376000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10466000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	52348000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	104979000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4899000
CY2022Q4	grts	Operating Lease Payment Under The Boston Lease OperatingLeasePaymentUnderTheBostonLease	79113000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	20967000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5294000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15673000
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	20000000
CY2022Q4	grts	Final Fee FinalFee	1150000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-1801000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	19349000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths	0
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo	0
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree	4407000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour	9396000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive	6197000
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	20000000
CY2022Q4	grts	Prepaid Expense For Research And Development PrepaidExpenseForResearchAndDevelopment	4241000
CY2021Q4	grts	Prepaid Expense For Research And Development PrepaidExpenseForResearchAndDevelopment	2672000
CY2022Q4	grts	Net Contract Asset NetContractAsset	0
CY2021Q4	grts	Net Contract Asset NetContractAsset	1385000
CY2022Q4	grts	Collaboration Receivable CollaborationReceivable	135000
CY2021Q4	grts	Collaboration Receivable CollaborationReceivable	688000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1158000
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1769000
CY2022Q4	grts	Interest And Other Receivables Current InterestAndOtherReceivablesCurrent	529000
CY2021Q4	grts	Interest And Other Receivables Current InterestAndOtherReceivablesCurrent	292000
CY2022Q4	grts	Facilities Related Deposits FacilitiesRelatedDeposits	384000
CY2021Q4	grts	Facilities Related Deposits FacilitiesRelatedDeposits	0
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	567000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	866000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7014000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7672000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5800000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	900000
CY2022	grts	Sharebased Compensation Arrangement By Sharebased Payment Award Options Cash Received SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived	200000
CY2021	grts	Sharebased Compensation Arrangement By Sharebased Payment Award Options Cash Received SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived	3400000
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	934000
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	1305000
CY2022Q4	grts	Prepaid Expense For Research And Development Non Current PrepaidExpenseForResearchAndDevelopmentNonCurrent	643000
CY2021Q4	grts	Prepaid Expense For Research And Development Non Current PrepaidExpenseForResearchAndDevelopmentNonCurrent	1047000
CY2022Q4	us-gaap	Prepaid Rent PrepaidRent	8162000
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	0
CY2022Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	9739000
CY2021Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	2352000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86894901
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86894901
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69047878
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69047878
CY2022	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Holders of the Company’s common stock are entitled to one vote per share.
CY2019Q4	grts	Maximum Securities Covered Under Registration Agreement MaximumSecuritiesCoveredUnderRegistrationAgreement	250000000.0
CY2022Q1	grts	Maximum Securities Covered Under Registration Agreement MaximumSecuritiesCoveredUnderRegistrationAgreement	250000000.0
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	26848627
CY2022	grts	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	3442567
CY2021	grts	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	10459576
CY2021	grts	Warrants Cancelled WarrantsCancelled	4872
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease	700000
CY2020	grts	Sharebased Compensation Arrangement By Sharebased Payment Award Options Cash Received SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.20
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.03
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.39
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3459187
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5107335
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.82
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M17D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	17153000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	3461915
CY2022	grts	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted	3518734
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3168561
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.73
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	194347
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.96
CY2022	grts	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled	1412026
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1129929
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.73
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4814394
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6951620
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.92
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y29D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1089000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3122952
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	9.24
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M24D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	9900000
CY2022	grts	Stock Based Compensation Expense And Awards Granted To Non Employees StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees	600000
CY2021	grts	Stock Based Compensation Expense And Awards Granted To Non Employees StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees	700000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	708800
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.29
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	350173
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.46
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	353300
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	5.29
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	144147
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	5.35
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	561526
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.38
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12557000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10552000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7110000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.076
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.102
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.079
CY2022	grts	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential	-0.004
CY2021	grts	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential	-0.001
CY2020	grts	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential	-0.006
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.012
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.019
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.028
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.011
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.018
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.094
CY2022	grts	Non Taxable Stock Premium NonTaxableStockPremium	0
CY2021	grts	Non Taxable Stock Premium NonTaxableStockPremium	0.025
CY2020	grts	Non Taxable Stock Premium NonTaxableStockPremium	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.283
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.337
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.403
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	33900000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	25200000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	109191000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	97575000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	14877000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	12271000
CY2022Q4	grts	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	6031000
CY2021Q4	grts	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	7684000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3786000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3184000
CY2022Q4	grts	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	9437000
CY2021Q4	grts	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	10633000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	700000
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2537000
CY2022Q4	grts	Deferred Tax Assets Other Depreciation DeferredTaxAssetsOtherDepreciation	449000
CY2021Q4	grts	Deferred Tax Assets Other Depreciation DeferredTaxAssetsOtherDepreciation	0
CY2022Q4	grts	Deferred Tax Assets Capitalized Expense DeferredTaxAssetsCapitalizedExpense	21434000
CY2021Q4	grts	Deferred Tax Assets Capitalized Expense DeferredTaxAssetsCapitalizedExpense	0
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	165905000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	133884000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	160877000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	127007000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5028000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	6877000
CY2022Q4	grts	Deferred Tax Liabilities Other Depreciation DeferredTaxLiabilitiesOtherDepreciation	0
CY2021Q4	grts	Deferred Tax Liabilities Other Depreciation DeferredTaxLiabilitiesOtherDepreciation	212000
CY2022Q4	grts	Deferred Tax Liabilities Operating Lease Right Of Uset Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets	5028000
CY2021Q4	grts	Deferred Tax Liabilities Operating Lease Right Of Uset Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets	6665000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	grts	Deferred Tax Assets Capitalized Expense DeferredTaxAssetsCapitalizedExpense	21400000
CY2022	grts	Ownership Interest Change Over Period OwnershipInterestChangeOverPeriod	P3Y
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5481000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4025000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2610000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1234000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1456000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1415000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6715000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5481000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4025000
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119687000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75082000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-105314000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90918333
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90918333
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78885186
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78885186
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37792365
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37792365
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.95
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.95
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.79
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.79
CY2022	grts	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	3442567
CY2021	grts	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	10459576
CY2021	grts	Warrants Cancelled WarrantsCancelled	4872
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	26848627
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	17016271
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7707343
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5879131
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4213738
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	500000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	400000

Files In Submission

Name	View Source	Status
0000950170-23-007022-index-headers.html	Edgar Link	pending
0000950170-23-007022-index.html	Edgar Link	pending
0000950170-23-007022.txt	Edgar Link	pending
0000950170-23-007022-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
grts-20221231.htm	Edgar Link	pending
grts-20221231.xsd	Edgar Link	pending
grts-ex10_22.htm	Edgar Link	pending
grts-ex23_1.htm	Edgar Link	pending
grts-ex31_1.htm	Edgar Link	pending
grts-ex31_2.htm	Edgar Link	pending
grts-ex32.htm	Edgar Link	pending
img97084416_0.jpg	Edgar Link	pending
img97084416_1.jpg	Edgar Link	pending
img97084416_2.jpg	Edgar Link	pending
img97084416_3.jpg	Edgar Link	pending
img97084416_4.jpg	Edgar Link	pending
img97084416_5.jpg	Edgar Link	pending
img97084416_6.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
grts-20221231_cal.xml	Edgar Link	unprocessable
grts-20221231_def.xml	Edgar Link	unprocessable
grts-20221231_lab.xml	Edgar Link	unprocessable
grts-20221231_pre.xml	Edgar Link	unprocessable
grts-20221231_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GRTSQ
Gritstone bio, Inc. Stock $grtsq

2023 Q1 Form 10-K Financial Statement

#000095017023007022 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GRTSQ Gritstone bio, Inc. Stock $grtsq

2023 Q1 Form 10-K Financial Statement

#000095017023007022 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GRTSQ
Gritstone bio, Inc. Stock $grtsq